Viewing Study NCT05970302

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:02 AM
Ignite Modification Date: 2026-01-29 @ 6:32 AM
Study NCT ID: NCT05970302
Status: RECRUITING
Last Update Posted: 2023-08-01
First Post: 2023-07-06
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Tislelizumab View
None Bevacizumab View
None Oxaliplatin View
None Capecitabine View
None MSS/pMMR View
None Metastatic Colorectal Cancer (mCRC) View
None RAS-mutated View
None First-Line View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Single-arm View
None Phase II View